AR029151A1 - Una sal cuaternaria de piperidina, su uso, un proceso para su preparacion, y una composicion farmaceutica que la contiene - Google Patents
Una sal cuaternaria de piperidina, su uso, un proceso para su preparacion, y una composicion farmaceutica que la contieneInfo
- Publication number
- AR029151A1 AR029151A1 ARP990105859A ARP990105859A AR029151A1 AR 029151 A1 AR029151 A1 AR 029151A1 AR P990105859 A ARP990105859 A AR P990105859A AR P990105859 A ARP990105859 A AR P990105859A AR 029151 A1 AR029151 A1 AR 029151A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- haloalkyl
- aralkyl
- heteroaryl
- aryl
- Prior art date
Links
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 7
- 125000003118 aryl group Chemical group 0.000 abstract 7
- 125000001188 haloalkyl group Chemical group 0.000 abstract 7
- 125000001072 heteroaryl group Chemical group 0.000 abstract 7
- 125000002947 alkylene group Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- -1 hydroxy, amino Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 abstract 3
- 125000004104 aryloxy group Chemical group 0.000 abstract 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 3
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 3
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000004475 heteroaralkyl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical group 0.000 abstract 2
- NDZYPHLNJZSQJY-QNWVGRARSA-N 1-(5-acetyl-4-methyl-1,3-thiazol-2-yl)-3-[(1r,2s)-2-[[(3s)-3-[(4-fluorophenyl)methyl]piperidin-1-yl]methyl]cyclohexyl]urea Chemical compound CC1=C(C(=O)C)SC(NC(=O)N[C@H]2[C@@H](CCCC2)CN2C[C@H](CC=3C=CC(F)=CC=3)CCC2)=N1 NDZYPHLNJZSQJY-QNWVGRARSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004966 cyanoalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Una sal cuaternaria de piperidina, seleccionada de los compuestos de formula (1)en la que uno de T y U es -N+R5- donde R5 es alquilo, haloalquilo, cianoalquilo, hidroxialquilo, alcoxialquilo, carboxialquilo, alcoxicarbonilalquilo, amidoalquilo, sulfonilaminoalquilo, o aralquilo y el otro es ûCH-; X- es un contraion farmacéuticamente aceptable; R1 y R2 son, independientemente uno de otro, hidrogeno o alquilo; m es un entero de 0 a 3 con la condicion de que cuando T es N+R5û entonces m es como mínimo 1; Ar y Ar1 son, independientemente uno de otro, arilo o heteroarilo; F es alquileno, alquenileno o un enlace; R es hidrogeno o alquilo; o R junto con bien R3 o R4 y los átomos a los que están unidos forman un carbociclo o un heterociclo; R3 y R4 son, independientemente uno de otro, hidrogeno, alquilo, alquenilo, haloalquilo, cicloalquilo, cicloalquilûalquilo, arilo, aralquilo, heteroarilo, heteroûaralquilo, heterociclilo, heterociclilalquilo, heteroalquilo, o û(alquileno)ûC(O)ûZ donde Z es alquilo, haloalquilo, alcoxi, haloalquiloxi, hidroxi, amino, amino mono- o disustituido, arilo, aralquilo, ariloxi, aralquiloxi, heteroarilo, heteroariloxi, o heteroaralquiloxi; E es ûC(O)N(R6)-; -SO2N(R6)-, -N(R7)C(O)N(R6)-, N(R7)C(O)N(R6)-, -N(R7)SO2N(R6)-, -N(R7)C(S)N(R6)-, -N(R7)C(O)- o ûN(R7)SO2- donde; R6 y R7 son, independientemente uno de otro, hidrogeno, alquilo, acilo, haloalquilo, cicloalquilo, cicloalquilalquilo, arilo, aralquilo, aralquenilo, heteroarilo, heteroaralquilo, heterocicloalquilo, heteroalquilo, o û(alquileno)ûC(O)ûZ donde Z es alquilo, haloalquilo, alcoxi, haloalquiloxi, hidroxi, amino, amino mono- o disustituido, arilo, aralquilo, ariloxi, aralquiloxi, heteroarilo, heteroariloxi, o heteroaralquiloxi; Q es ûCO- o una cadena de alquileno interrumpida opcionalmente por ûC (O)-, -NR8-, -O-, -S(O)0-2-, -C(O)N(R8) -, -N(R8)C(O)-, -N(R8)SO2-, -SO2N(R8)-, -N(R9)C(O)N(R10)-, -N (R9)SO2N(R10)- o ûN(R9)C(S)N(R10)- donde: R8, R9 y R10 son independientemente uno de otro, hidrogeno, alquilo, acilo, haloalquilo, cicloalquilo, cicloalquilalquilo, arilo, aralquilo, aralquenilo, heteroarilo, heteroaralquilo, heterociclilalquilo, heteroalquilo, o û (alquileno)ûC(O)ûZ, donde Z es alquilo, haloalquilo, alcoxi, haloalquiloxi, hidroxi, amino, amino mono- o disustituido, arilo, aralquilo, ariloxi, aralquiloxi, heteroarilo, heteroariloxi, o heteroaralquiloxi; y profármacos, isomeros individuales, mezclas de isomeros y sales farmacéuticamente aceptables de los mismos; proceso para prepararla; composicion farmacéutica que la contiene, y su uso, para la preparacion de un medicamento que la comprende como ingrediente activo para el tratamiento de una enfermedad tratable por la administracion de un antagonista de CCR-3, en especial el asma.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10929398P | 1998-11-20 | 1998-11-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR029151A1 true AR029151A1 (es) | 2003-06-18 |
Family
ID=22326896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990105859A AR029151A1 (es) | 1998-11-20 | 1999-11-18 | Una sal cuaternaria de piperidina, su uso, un proceso para su preparacion, y una composicion farmaceutica que la contiene |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6342509B1 (es) |
| EP (1) | EP1131290B1 (es) |
| JP (1) | JP3421323B2 (es) |
| KR (1) | KR20010081034A (es) |
| CN (1) | CN1326440A (es) |
| AR (1) | AR029151A1 (es) |
| AT (1) | ATE386720T1 (es) |
| AU (1) | AU1774600A (es) |
| BR (1) | BR9915735A (es) |
| CA (1) | CA2351631A1 (es) |
| CO (1) | CO5140118A1 (es) |
| DE (2) | DE69938193D1 (es) |
| ES (1) | ES2158813B1 (es) |
| FR (1) | FR2786179B1 (es) |
| GB (1) | GB2343894B (es) |
| IT (1) | IT1308657B1 (es) |
| PE (1) | PE20001401A1 (es) |
| TR (1) | TR200101397T2 (es) |
| WO (1) | WO2000031033A1 (es) |
| ZA (1) | ZA200103940B (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1179341B1 (en) | 1999-05-18 | 2005-11-09 | Teijin Limited | Remedies or preventives for diseases in association with chemokines |
| CA2378499A1 (en) | 1999-08-04 | 2001-02-15 | Teijin Limited | Cyclic amine ccr3 antagonists |
| AR028948A1 (es) | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | Compuestos novedosos |
| BR0114323A (pt) | 2000-09-29 | 2003-07-01 | Glaxo Group Ltd | Composto ou um seu sal ou solvato farmaceuticamente aceitável, composição farmacêutica, uso do composto ou de um seu sal ou solvato farmaceuticamente aceitável, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para preparar o composto |
| ATE374198T1 (de) * | 2000-12-19 | 2007-10-15 | Hoffmann La Roche | Substituierte pyrrolidine als ccr-3- rezeptorantagonisten |
| CN100384838C (zh) | 2001-04-27 | 2008-04-30 | 三菱制药株式会社 | 新的苄基哌啶化合物 |
| GB0114699D0 (en) * | 2001-06-15 | 2001-08-08 | Novartis Ag | Organic compounds |
| TW200303304A (en) | 2002-02-18 | 2003-09-01 | Astrazeneca Ab | Chemical compounds |
| EP1599472A1 (en) * | 2003-02-27 | 2005-11-30 | F. Hoffmann-La Roche Ag | Ccr-3 receptor antagonists |
| RU2366655C2 (ru) | 2003-03-14 | 2009-09-10 | Оно Фармасьютикал Ко., Лтд. | Азотсодержащие гетероциклические производные и лекарственные средства, содержащие их в качестве активного ингредиента |
| EP1619193A4 (en) | 2003-04-18 | 2010-08-11 | Ono Pharmaceutical Co | SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF |
| MXPA06004304A (es) * | 2003-10-24 | 2006-06-05 | Hoffmann La Roche | Antagonistas del receptor ccr-3. |
| SE0400208D0 (sv) * | 2004-02-02 | 2004-02-02 | Astrazeneca Ab | Chemical compounds |
| TW200619212A (en) | 2004-09-08 | 2006-06-16 | Mitsubishi Pharma Corp | Morpholine derivatives |
| CN101775013A (zh) | 2004-09-13 | 2010-07-14 | 小野药品工业株式会社 | 含氮杂环衍生物及含有其作为活性成分的药物 |
| JPWO2006129679A1 (ja) | 2005-05-31 | 2009-01-08 | 小野薬品工業株式会社 | スピロピペリジン化合物およびその医薬用途 |
| TW200738635A (en) * | 2005-08-02 | 2007-10-16 | Astrazeneca Ab | New salt |
| TW200738634A (en) | 2005-08-02 | 2007-10-16 | Astrazeneca Ab | New salt |
| TW200734305A (en) * | 2005-08-02 | 2007-09-16 | Astrazeneca Ab | New salt III |
| PT1942108E (pt) | 2005-10-28 | 2013-10-24 | Ono Pharmaceutical Co | Composto com um grupo básico e a sua utilização |
| WO2007058322A1 (ja) | 2005-11-18 | 2007-05-24 | Ono Pharmaceutical Co., Ltd. | 塩基性基を含有する化合物およびその用途 |
| CA2644368A1 (en) | 2006-03-10 | 2007-09-20 | Ono Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient |
| US8618122B2 (en) | 2006-05-16 | 2013-12-31 | Ono Pharmaceutical Co., Ltd. | Compound having acidic group which may be protected, and use thereof |
| WO2008016006A1 (fr) | 2006-07-31 | 2008-02-07 | Ono Pharmaceutical Co., Ltd. | Composé auquel un groupe cyclique est lié par une liaison spiro et son utilisation |
| DE102008020746A1 (de) * | 2008-04-25 | 2009-10-29 | Saltigo Gmbh | Verfahren zur Herstellung von quarternären Salzen von Piperidyl Estern der Mandelsäure |
| WO2010129351A1 (en) | 2009-04-28 | 2010-11-11 | Schepens Eye Research Institute | Method to identify and treat age-related macular degeneration |
| KR101180174B1 (ko) * | 2010-04-23 | 2012-09-05 | 동아제약주식회사 | 신규한 벤즈아미드 유도체 |
| US9771348B2 (en) | 2013-07-25 | 2017-09-26 | Dong-A St Co., Ltd | Method for preparing benzamide derivative, novel intermediate used in preparation of benzamide, and method for preparing novel intermediate |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1574418A (en) * | 1976-11-16 | 1980-09-03 | Anphar Sa | Piperidine derivatives |
| US4163784A (en) * | 1978-03-09 | 1979-08-07 | Pfizer Inc. | Heterocyclylcarbonyl derivatives of urea, agents for dissolution of gallstones |
| DK159420C (da) | 1983-03-09 | 1991-03-11 | Ciba Geigy Ag | N-(piperidinyl-alkyl)-carboxamider og salte deraf, farmaceutiske praeparater indeholdende disse forbindelser samt anvendelsen af forbindelserne til fremstilling af antipsykotiske farmaceutiske praeparater |
| US4579947A (en) | 1983-06-16 | 1986-04-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted phenylalkylpiperazinylpropyl (ureas or thioureas) useful for treatment of immunological, inflammatory and allergic disorder |
| DK623586A (da) | 1985-12-27 | 1987-06-28 | Eisai Co Ltd | Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne |
| US4857330A (en) | 1986-04-17 | 1989-08-15 | Alza Corporation | Chlorpheniramine therapy |
| FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| CA2005741C (en) | 1988-12-26 | 1998-06-02 | Hiroyoshi Hidaka | Quinoline sulfonoamino compounds having vessel smooth muscle relaxation activity |
| FI97540C (fi) | 1989-11-06 | 1997-01-10 | Sanofi Sa | Menetelmä terapeuttisesti käyttökelpoisten, aromaattisesti substituoitujen piperidiini- ja piperatsiinijohdannaisten valmistamiseksi |
| JPH041128A (ja) | 1990-03-07 | 1992-01-06 | Ajinomoto Co Inc | 抗不整脈薬 |
| US5143923B1 (en) | 1991-04-29 | 1993-11-02 | Hoechst-Roussel Pharmaceuticals Incorporated | Benzoisothiazole-and benzisoxazole-3-carboxamides |
| FR2677019B1 (fr) | 1991-05-27 | 1994-11-25 | Pf Medicament | Nouvelles piperidines disubstituees-1,4, leur preparation et leur application en therapeutique. |
| US5438064A (en) * | 1991-12-23 | 1995-08-01 | American Home Products Corporation | Derivatives of 4-anilinoquinoline-3-carboxamide as analgesic agents |
| FR2688219B1 (fr) | 1992-03-03 | 1994-07-08 | Sanofi Elf | Sels d'ammonium quaternaires de composes aromatiques amines, leur preparation et compositions pharmaceutiques les contenant. |
| DK60893D0 (da) | 1993-05-26 | 1993-05-26 | Novo Nordisk As | Piperidinderivater, deres fremstilling og anvendelse |
| WO1995000481A1 (en) | 1993-06-23 | 1995-01-05 | Merrell Dow Pharmaceuticals Inc. | Piperidin-1-yl-2,2-dialkylpropanonearylsulfonamide derivatives |
| EP0661266A1 (en) | 1993-12-27 | 1995-07-05 | Toa Eiyo Ltd. | Substituted cyclic amine compounds as 5HT2 antagonists |
| ES2179881T3 (es) | 1994-08-19 | 2003-02-01 | Abbott Lab | Antagonistas de endotelina. |
| JPH0977742A (ja) * | 1995-09-12 | 1997-03-25 | Kyorin Pharmaceut Co Ltd | 新規なベンズアミド誘導体 |
| CA2188485A1 (en) | 1995-11-17 | 1997-05-18 | Ronald J. Mattson | Piperidinylethylamide derivatives as serotonergic agents |
| GB9523526D0 (en) | 1995-11-17 | 1996-01-17 | Zeneca Ltd | Therapeutic compounds |
| CA2197364A1 (en) | 1996-02-15 | 1997-08-16 | Toshikazu Suzuki | Phenol compound and process for preparing the same |
| JP4150435B2 (ja) * | 1996-04-18 | 2008-09-17 | 株式会社資生堂 | アルキレンジアミン誘導体及び抗潰瘍剤、抗菌剤 |
| US6323206B1 (en) * | 1996-07-12 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| TW498067B (en) | 1996-07-19 | 2002-08-11 | Hoffmann La Roche | 4-hydroxy-piperidine derivatives |
| AU3633997A (en) | 1996-07-29 | 1998-02-20 | Banyu Pharmaceutical Co., Ltd. | Chemokine receptor antagonists |
| US6136827A (en) | 1997-07-25 | 2000-10-24 | Merck & Co., Inc. | Cyclic amine modulations of chemokine receptor activity |
| IL125658A0 (en) | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
| JP2002501052A (ja) * | 1998-01-21 | 2002-01-15 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | ケモカイン受容体アンタゴニストおよびその使用方法 |
| PL348375A1 (en) | 1998-11-20 | 2002-05-20 | Hoffmann La Roche | Pyrrolidine derivatives-ccr-3 receptor antagonists |
| CA2346933A1 (en) | 1998-12-18 | 2000-06-22 | Dupont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
-
1999
- 1999-11-08 AT AT99960962T patent/ATE386720T1/de not_active IP Right Cessation
- 1999-11-08 TR TR2001/01397T patent/TR200101397T2/xx unknown
- 1999-11-08 BR BR9915735-7A patent/BR9915735A/pt not_active IP Right Cessation
- 1999-11-08 WO PCT/EP1999/008554 patent/WO2000031033A1/en not_active Ceased
- 1999-11-08 CN CN99813286A patent/CN1326440A/zh active Pending
- 1999-11-08 JP JP2000583861A patent/JP3421323B2/ja not_active Expired - Fee Related
- 1999-11-08 AU AU17746/00A patent/AU1774600A/en not_active Abandoned
- 1999-11-08 DE DE69938193T patent/DE69938193D1/de not_active Expired - Lifetime
- 1999-11-08 KR KR1020017006393A patent/KR20010081034A/ko not_active Withdrawn
- 1999-11-08 CA CA002351631A patent/CA2351631A1/en not_active Abandoned
- 1999-11-08 EP EP99960962A patent/EP1131290B1/en not_active Expired - Lifetime
- 1999-11-16 PE PE1999001160A patent/PE20001401A1/es not_active Application Discontinuation
- 1999-11-17 GB GB9927228A patent/GB2343894B/en not_active Expired - Fee Related
- 1999-11-18 US US09/442,799 patent/US6342509B1/en not_active Expired - Fee Related
- 1999-11-18 CO CO99072637A patent/CO5140118A1/es unknown
- 1999-11-18 AR ARP990105859A patent/AR029151A1/es unknown
- 1999-11-19 DE DE19955793A patent/DE19955793A1/de not_active Withdrawn
- 1999-11-19 ES ES009902546A patent/ES2158813B1/es not_active Expired - Fee Related
- 1999-11-19 FR FR9914562A patent/FR2786179B1/fr not_active Expired - Fee Related
- 1999-11-22 IT IT1999TO001021A patent/IT1308657B1/it active
-
2001
- 2001-05-15 ZA ZA200103940A patent/ZA200103940B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1131290A1 (en) | 2001-09-12 |
| CO5140118A1 (es) | 2002-03-22 |
| ITTO991021A1 (it) | 2001-05-22 |
| FR2786179A1 (fr) | 2000-05-26 |
| JP2002530375A (ja) | 2002-09-17 |
| ES2158813A1 (es) | 2001-09-01 |
| ITTO991021A0 (it) | 1999-11-22 |
| US6342509B1 (en) | 2002-01-29 |
| TR200101397T2 (tr) | 2001-11-21 |
| ZA200103940B (en) | 2002-08-15 |
| CA2351631A1 (en) | 2000-06-02 |
| PE20001401A1 (es) | 2000-12-15 |
| FR2786179B1 (fr) | 2001-08-10 |
| GB2343894A (en) | 2000-05-24 |
| IT1308657B1 (it) | 2002-01-09 |
| GB9927228D0 (en) | 2000-01-12 |
| EP1131290B1 (en) | 2008-02-20 |
| WO2000031033A1 (en) | 2000-06-02 |
| JP3421323B2 (ja) | 2003-06-30 |
| ES2158813B1 (es) | 2002-03-16 |
| BR9915735A (pt) | 2001-09-04 |
| CN1326440A (zh) | 2001-12-12 |
| ATE386720T1 (de) | 2008-03-15 |
| GB2343894B (en) | 2001-07-25 |
| DE69938193D1 (de) | 2008-04-03 |
| KR20010081034A (ko) | 2001-08-25 |
| DE19955793A1 (de) | 2000-05-25 |
| AU1774600A (en) | 2000-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR029151A1 (es) | Una sal cuaternaria de piperidina, su uso, un proceso para su preparacion, y una composicion farmaceutica que la contiene | |
| AR017796A1 (es) | DERIVADOS DE 2-ARIL-8-OXODIHIDROPURINA, PROCEDIMIENTOS PARA PREPARARLOS, COMPUESTOS INTERMEDIARIOS DE APLICACIoN EN DICHOS PROCEDIMIENTOS, COMPOSICIONES FARMACEUTICAS, Y SU USO PARA LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ESTADOS DE ANSIEDAD. | |
| UY27333A1 (es) | Nucleótidos 4` sustituidos | |
| HUP0302526A2 (hu) | Makrolid vegyületek, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
| AR029150A1 (es) | Un derivado de piperidina, su empleo, un procedimiento para prepararlo y una composicin farmaceutica que lo comprende. | |
| ES2083359T3 (es) | Piperidinas 1,4-substituidas como inhibidores de la acetilcolinesterasa y su utilizacion en el tratamiento de la enfermedad de alzheimer. | |
| BG98793A (bg) | Нови производни на аминокиселините,методи за тяхното получаване и фармацевтични състави,съдържащи тези съединения | |
| CO4810375A1 (es) | Derivados de 9-amino-3-ceto eritromicina | |
| AR036674A1 (es) | Inhibidores de fosfodiesterasa v de guanina de policiclicos, composicion farmaceutica, y el uso de dichos compuestos para la preparacion de medicamentos para tratar desordenes fisiologicos | |
| AR012315A1 (es) | Derivados de ditiolan y el uso de los mismos en la fabricacion de un medicamento. | |
| AR037534A1 (es) | Derivado de adamantano, su uso en la fabricacion de un medicamento para usar en terapia, composicion farmaceutica, proceso para la preparacion de dicho compuesto y dicha composicion y compuestos intermediarios | |
| AR010376A1 (es) | Compuestos con efecto analgesico, su uso para la fabricacion de medicamentos, agentes de diagnostico, composicion farmaceutica, procedimiento para la preparacion de dichos compuestos y compuestos intermediarios | |
| AR018732A1 (es) | Iminoazucares alquilados para prevenir, reducir o revertir la resistencia a la multidroga en el tratamiento quimioterapeutico y composicionfarmaceutica que los contiene. | |
| BRPI9807222B8 (pt) | compostos inibidores da atividade de cetp, seus usos e composições farmacêuticas | |
| UY27876A1 (es) | Prodrogas 2' y 3 ' de nucleósidos para tratar infecciones de flaviviridae. | |
| CU23132A3 (es) | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos | |
| UY25142A1 (es) | Antagonistas del receptor ccr-3 | |
| AR018634A1 (es) | Derivados de benzo(b)tiepin-1,1,-dioxido, procedimiento para su preparacion, medicamentos conteniendo estos compuestos, procedimiento para la preparacion de medicamentos y su empleo para la preparacion de medicamentos. | |
| AR020032A1 (es) | Derivados de 1,3 -metil eritromicina. | |
| DOP2006000063A (es) | Derivados de ciclopropanocarboxamida | |
| EA200200417A1 (ru) | Фармацевтически активные производные сульфонамида | |
| RU2005105576A (ru) | Производные плевромутилина в качестве противомикроюных средств | |
| AR064253A1 (es) | Compuestos de biciclocarboxiamida sustituidos composiciones farmaceuticas y una combinacion que los incluye y su uso en fabaricacion de un medicamento para el tratamiento de enfermedades mediadas por la actividad del receptor vr1 | |
| ES2059804T3 (es) | Procedimiento de preparacion de eteres de oxima de propenona. | |
| ES2061462T3 (es) | Compuestos cefemo, procedimientos para su preparacion y composiciones farmaceuticas que los contienen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |